CR20200151A - Compuestos bicíclicos y métodos de utilización de los mismos - Google Patents

Compuestos bicíclicos y métodos de utilización de los mismos

Info

Publication number
CR20200151A
CR20200151A CR20200151A CR20200151A CR20200151A CR 20200151 A CR20200151 A CR 20200151A CR 20200151 A CR20200151 A CR 20200151A CR 20200151 A CR20200151 A CR 20200151A CR 20200151 A CR20200151 A CR 20200151A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
rip1 kinase
bicyclic compounds
compounds
ring
Prior art date
Application number
CR20200151A
Other languages
English (en)
Inventor
Snahel Patel
Craig Stivala
Guiling Zhao
Huifen Chen
Blake Daniels
Gregory Hamilton
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20200151A publication Critical patent/CR20200151A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona nuevos compuestos que presentan la fórmula general I o sales farmacéuticamente aceptable de los mismos, en los que: RA, RB1, RB2, el anillo A y el anillo B son tal como se indica en la presente memoria, composiciones farmacéuticas que incluyen los compuestos y métodos de utilización de los compuestos.
CR20200151A 2017-10-11 2018-10-10 Compuestos bicíclicos y métodos de utilización de los mismos CR20200151A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570892P 2017-10-11 2017-10-11
PCT/EP2018/077656 WO2019072942A1 (en) 2017-10-11 2018-10-10 BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1

Publications (1)

Publication Number Publication Date
CR20200151A true CR20200151A (es) 2020-05-23

Family

ID=63840848

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200151A CR20200151A (es) 2017-10-11 2018-10-10 Compuestos bicíclicos y métodos de utilización de los mismos

Country Status (19)

Country Link
US (1) US11673892B2 (es)
EP (1) EP3694858B1 (es)
JP (1) JP7362600B2 (es)
KR (1) KR20200070297A (es)
CN (1) CN111201229A (es)
AU (1) AU2018348930A1 (es)
BR (1) BR112020007067A2 (es)
CA (1) CA3078653A1 (es)
CL (1) CL2020000944A1 (es)
CO (1) CO2020004977A2 (es)
CR (1) CR20200151A (es)
IL (1) IL273443A (es)
MA (1) MA50356A (es)
MX (1) MX2020003439A (es)
PE (1) PE20211246A1 (es)
PH (1) PH12020550253A1 (es)
RU (1) RU2020114670A (es)
SG (1) SG11202003283TA (es)
WO (1) WO2019072942A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
ES2973661T3 (es) 2017-07-14 2024-06-21 Hoffmann La Roche Compuestos de cetona bicíclica y procedimientos de uso de los mismos
EP3704097B1 (en) 2017-10-31 2023-10-25 F. Hoffmann-La Roche AG Bicyclic sulfones and sulfoxides and methods of use thereof
JP2022516651A (ja) * 2019-01-11 2022-03-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピロロトリアゾールケトン化合物及びその使用方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
WO1992004343A1 (en) * 1990-09-04 1992-03-19 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
WO1998056376A1 (en) 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
PL213199B1 (pl) 2000-08-10 2013-01-31 Pharmacia Italia Spa Zwiazek bicyklo-pirazolowy, sposób wytwarzania go, jego kompozycja farmaceutyczna, oraz kombinatoryczna biblioteka chemiczna
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2002094833A1 (en) 2001-05-24 2002-11-28 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2791165C (en) 2002-12-03 2015-02-24 Blanchette Rockefeller Neurosciences Institute A conjugate comprising cholesterol linked to tetracycline
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
BRPI0807346B8 (pt) 2007-02-07 2021-05-25 Pfizer derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldeído como inibidores de pkc, seu uso e composição farmacêutica que os compreende
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
JP6068464B2 (ja) 2011-07-15 2017-01-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド γ−セクレターゼ調節剤としての新規な置換インドール誘導体
CN104271566B (zh) 2012-05-22 2017-05-31 霍夫曼-拉罗奇有限公司 取代的联吡啶胺及其用途
BR112015016395A2 (pt) 2013-01-18 2017-07-11 Hoffmann La Roche pirazóis 3-substituídos e uso como inibidores de dlk
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
CN105164114B (zh) 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
JP6229042B2 (ja) 2013-05-01 2017-11-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
CA2988601C (en) 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
US20200283446A1 (en) 2020-09-10
KR20200070297A (ko) 2020-06-17
BR112020007067A2 (pt) 2020-10-06
EP3694858A1 (en) 2020-08-19
CL2020000944A1 (es) 2020-08-21
PE20211246A1 (es) 2021-07-13
PH12020550253A1 (en) 2021-02-22
JP7362600B2 (ja) 2023-10-17
CO2020004977A2 (es) 2020-05-05
CN111201229A (zh) 2020-05-26
MA50356A (fr) 2021-04-21
EP3694858B1 (en) 2023-01-11
WO2019072942A1 (en) 2019-04-18
US11673892B2 (en) 2023-06-13
SG11202003283TA (en) 2020-05-28
AU2018348930A1 (en) 2020-03-26
IL273443A (en) 2020-05-31
JP2020536915A (ja) 2020-12-17
RU2020114670A (ru) 2021-11-12
CA3078653A1 (en) 2019-04-18
MX2020003439A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
PH12016501440A1 (en) Novel heterocyclic compounds
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MY194116A (en) Pharmaceutical compounds
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
TW201613864A (en) Novel compounds
NZ735631A (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
MX2018014813A (es) Composiciones antibacterianas.
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
JOP20190163B1 (ar) منشط nrf2
IN2014MU00859A (es)
MX2018010652A (es) Composiciones farmaceuticas.
MX2016012646A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
EA202090930A1 (ru) Соединения, пригодные для ингибирования cdk7
MY182697A (en) Bicyclic lactams and methods of use thereof